Agilon Health CEO Steven Sell buys $67k in company stock

Agilon Health, Inc. (NYSE:AGL) CEO and President Steven Sell has made a notable investment in the company's stock, according to a recent SEC filing. On September 12, Sell purchased 20,000 shares of Agilon Health's common stock at a weighted average price of $3.3594 per share, totaling approximately $67,188.


The transaction was carried out in multiple trades, with prices ranging from $3.31 to $3.37 per share. The shares acquired are held in a trust, as indicated by the filing. Following this purchase, the CEO now owns a total of 67,590 shares directly through the trust. The SEC filing also notes that Sell's total holdings include restricted stock units, which contribute to an aggregate of 328,447 shares of common stock under his direct ownership.


Investors often look to insider buying as a signal of confidence in the company's future prospects. The purchase by Sell aligns with this narrative, potentially indicating his belief in the long-term value of Agilon Health.


Agilon Health specializes in healthcare services and has positioned itself as a partner for primary care physicians in managing the complexities of patient care. The company's stock performance and strategic initiatives are closely watched by investors seeking opportunities in the healthcare sector.


For further details on the CEO's stock transactions, interested parties can refer to the full information provided in the SEC filing.



In other recent news, agilon health, a healthcare organization, experienced a revenue shortfall in its second-quarter earnings report, leading Deutsche Bank to reduce its price target for the company to $4.00. Despite this, agilon health's Medicare Advantage membership saw a year-over-year increase of 38%, reaching 513,000 members. However, the company's growth was slightly hampered by delays in signing new payer contracts.


The company's second-quarter revenue was reported at $1.48 billion, a 38% increase year-over-year, but still below the consensus estimate of $1.56 billion. The discrepancy was largely attributed to retroactive contract cancellations. Despite the revenue miss, agilon health reported better-than-expected adjusted EBITDA figures, with a loss of $2.8 million compared to the anticipated $7.9 million loss forecasted by analysts.


In other developments, agilon health has adjusted its full-year guidance while reporting substantial growth in its Medicare Advantage membership and revenues. The company anticipates being free cash flow positive starting in 2026 and is focused on improving payer relationships and managing Part B drug costs. Despite facing challenges such as retroactive contract terminations and increased medical services expenses, agilon health continues to position itself for future growth in the healthcare market.
InvestingPro Insights


Agilon Health, Inc. (NYSE:AGL) has recently been under the spotlight with CEO Steven Sell's purchase of company stock, indicating a potential vote of confidence in the firm's prospects. In light of this development, a closer look at some key metrics and InvestingPro Tips for Agilon Health can provide investors with a deeper understanding of the company's financial health and market position.


InvestingPro Data shows that Agilon Health holds a market capitalization of approximately $1.35 billion, reflecting its size and relevance in the healthcare sector. Despite the recent insider buying, the company's stock has experienced significant volatility, as evidenced by a 52-week low price percentage of just 16.15%. This suggests that the stock is currently trading near its lowest price point over the past year.


One of the InvestingPro Tips highlights that Agilon Health's stock is in oversold territory according to the Relative Strength Index (RSI), which could suggest a potential for rebound if market sentiment shifts. Moreover, the company is trading at a low revenue valuation multiple, which might be an indicator of undervaluation relative to its sales.


However, it's important to note that Agilon Health has been grappling with challenges as well. The company is not expected to be profitable this year, and analysts have revised their earnings expectations downwards for the upcoming period. Additionally, Agilon Health has weak gross profit margins, which could be a concern for its operational efficiency.


For investors seeking a comprehensive analysis of Agilon Health, there are additional InvestingPro Tips available. These include insights into the company's cash position, stock performance over various time frames, and profitability metrics over the last twelve months. In total, there are 12 additional tips listed on InvestingPro, which can be accessed for more detailed investment research and analysis.


As the healthcare industry continues to evolve, investors will be watching Agilon Health closely for signs of improvement and growth. The recent insider buying by the CEO may be just one piece of the puzzle in assessing the company's future trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Source: Investing.com